SG Americas Securities LLC Takes Position in Replimune Group, Inc. (NASDAQ:REPL)

SG Americas Securities LLC acquired a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 22,917 shares of the company’s stock, valued at approximately $251,000.

A number of other hedge funds have also made changes to their positions in REPL. Millennium Management LLC boosted its stake in Replimune Group by 575.1% during the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after purchasing an additional 2,656,173 shares during the period. Goldman Sachs Group Inc. boosted its stake in Replimune Group by 300.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock valued at $18,874,000 after purchasing an additional 1,679,553 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Replimune Group by 12.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock valued at $53,505,000 after purchasing an additional 699,679 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in Replimune Group during the 1st quarter valued at approximately $1,088,000. Finally, Acadian Asset Management LLC bought a new stake in Replimune Group during the 1st quarter valued at approximately $927,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on REPL. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Roth Mkm assumed coverage on Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Finally, HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a report on Monday, September 16th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $16.80.

Insider Activity at Replimune Group

In related news, CFO Emily Luisa Hill sold 8,938 shares of the business’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total value of $90,988.84. Following the sale, the chief financial officer now owns 101,057 shares of the company’s stock, valued at $1,028,760.26. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 20.60% of the stock is owned by insiders.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $11.35 on Tuesday. The business’s 50 day moving average is $10.81 and its 200-day moving average is $8.89. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $697.06 million, a PE ratio of -3.50 and a beta of 1.21. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $15.18.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.10. Sell-side analysts predict that Replimune Group, Inc. will post -3.11 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.